GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (TSXV:HEM) » Definitions » Deferred Policy Acquisition Costs

Hemostemix (TSXV:HEM) Deferred Policy Acquisition Costs


View and export this data going back to 2012. Start your Free Trial

What is Hemostemix Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Hemostemix Business Description

Industry
Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
Executives
Thomas Smeenk Director
Peter Alan Lacey Director
Loran Swanberg Director
Blake Wood 10% Security Holder
Ravi Jain Senior Officer